About this trial
This study will develop and evaluate a mobile-based co-design intervention (CesiKids) to enhance psychosocial resilience in hospitalized adolescents aged 12-18 diagnosed with cancer. The program will be created using Bronfenbrenner's Ecological Systems Theory and designed in collaboration with nurses, recovered adolescents, and parents. A randomized controlled design will be used. The intervention group will participate in a four-week structured program, while the control group will receive standard care. Psychosocial resilience and coping outcomes will be assessed at baseline, post-intervention, and follow-up. This research aims to offer an evidence-based, scalable model to support resilience among adolescents with cancer in clinical settings.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Parents have provided informed consent after receiving information,
The child has given assent to participate after being informed,
The child is between 12 and 18 years of age,
The child has been diagnosed with cancer and is currently receiving inpatient treatment,
Disqualifiers
Receiving hematopoietic stem cell transplantation treatment,
Having developed a relapse after remission,
Experiencing communication difficulties (e.g., intellectual disability, visual impairment, etc.),
Having a psychiatric diagnosis made by a psychiatrist,
Trial design
Parallel
Treatments tested in this trial
CesiKids Mobile-Based Psychological Resilience Program
Other interventionThe CesiKids Program will be a nurse-led, AI-supported mobile intervention to enhance psychological resilience in adolescents diagnosed with cancer. Grounded in Bronfenbrenner's Bioecological Theory, it will address interactions between adolescents and their family, peers, and clinical environments. Developed through a co-design process with nurses, recovered adolescents, and parents, the program will include AI-driven adaptive feedback and emotional support features. Delivered over four weeks with structured digital sessions, CesiKids will promote emotional regulation, coping, and resilience through interactive storytelling, reflection, and personalized guidance. This integrative model will combine ecological principles, AI personalization, and participatory design to create an innovative psychosocial care approach for hospitalized adolescents with cancer.
Treatment groups
Trial outcomes
Primary outcomes
Child and Youth Resilience Measure (CYRM-R)
The Child and Youth Resilience Measure-Revised (CYRM-R) is a multidimensional scale based on the socio-ecological model to assess resilience. The 28-item original version was developed by Liebenberg, Ungar, and Van de Vijver through the International Resilience Project. Later, Liebenberg, Ungar, and LeBlanc created a 12-item short form with three subscales: individual, relational, and contextual resilience. Factor loadings ranged from .39-.88, and Cronbach's alpha was .84. Items are rated on a five-point Likert scale (1-5), with higher scores indicating greater resilience. The Turkish adaptation by Arslan showed strong reliability (α = .91; item-total correlations = .45-.79). In this study, the CYRM-R will assess changes in adolescents' resilience after the CesiKids program.
Secondary outcomes
Pediatric Cancer Coping Scale (PCCS)
The scale was developed by Wu et al. to assess coping strategies among adolescents aged 7-18 diagnosed with cancer. The Turkish validity and reliability study was conducted by Şengül and Törüner with children in the same age range. The scale includes 33 items across three dimensions: cognitive coping, problem-focused coping, and defensive coping. Items are rated on a 0-3 scale, with total scores ranging from 0 to 99. Higher scores indicate stronger coping strategies. The original version showed a Cronbach's alpha of 0.91, while the Turkish version reported 0.77. The scale has been used to assess coping levels in pediatric oncology populations. In this study, it will be used to evaluate the effectiveness of the CesiKids program in enhancing adolescents' coping skills with cancer.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: